Anti-CD20 Monoclonal Antibodies Market Report 2026

The anti-cd20 monoclonal antibodies market size has grown strongly in recent years. It will grow from $9 billion in 2025 to $9.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to approval and widespread use of rituximab, rising incidence of non-hodgkin's lymphoma and chronic lymphocytic leukemia, growing awareness of targeted therapies, availability of hospital pharmacy distribution channels, expansion of intravenous administration routes.

The anti-cd20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to development of obinutuzumab and ofatumumab biosimilars, increasing adoption of subcutaneous formulations, growing investment in research and academia, expansion of ambulatory care centers, increasing demand for anti-cd20 therapies in multiple autoimmune diseases. Major trends in the forecast period include rising adoption of monoclonal antibody therapies for b-cell malignancies, development of biosimilars and next-generation anti-cd20 antibodies, expansion of subcutaneous and patient-friendly administration routes, increasing focus on personalized and targeted immunotherapy, growing clinical trials and research in autoimmune and oncology indications.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the anti-CD20 monoclonal antibodies market in the coming years. Autoimmune diseases arise when the immune system mistakenly recognizes the body’s own cells as harmful and mounts an immune response against them. The incidence of autoimmune disorders is rising due to increased exposure to environmental pollutants, which can disrupt immune regulation and trigger immune attacks on healthy tissues. Anti-CD20 monoclonal antibodies treat autoimmune conditions by depleting B cells that contribute to autoantibody production and inflammatory processes. These therapies help modulate immune activity and alleviate disease symptoms. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 562,378 Australians are projected to be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases in that year. By 2040, this figure is expected to increase by 33% to 748,721 individuals, reflecting an additional 186,343 Australians affected by RA compared with 2025. Therefore, the growing burden of autoimmune diseases is supporting the expansion of the anti-CD20 monoclonal antibodies market.

Major companies operating in the anti-CD20 monoclonal antibody market are concentrating on the development of advanced therapies, such as obinutuzumab, to more effectively target resistant or relapsed B-cell-related conditions. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody engineered to identify and eliminate CD20-positive B cells involved in certain autoimmune disorders and blood cancers. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration accepted a supplemental Biologics License Application for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. This submission was supported by positive results from the Phase III REGENCY study, which demonstrated improved complete renal response when obinutuzumab was combined with standard therapy compared with standard therapy alone. This milestone positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such clinical benefit in lupus nephritis, a serious inflammatory condition associated with lupus that can progress to kidney failure.

In August 2023, TG Therapeutics, a US-based producer of anti-CD20 monoclonal antibodies, entered into a partnership with Neuraxpharm to broaden global access to innovative multiple sclerosis treatments. The collaboration aims to commercialize BRIUMVI, a CD20-targeted monoclonal antibody therapy, across international markets and accelerate its availability for patients with relapsing multiple sclerosis outside the United States. Neuraxpharm is a Germany-based pharmaceutical company.

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-cd20 monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the anti-CD20 monoclonal antibodies market by increasing costs for imported biologics, active pharmaceutical ingredients (APIs), and manufacturing equipment. Segments such as rituximab and next-generation monoclonal antibodies are most affected, with regions including Europe and Asia-Pacific facing notable import duties. This has led to higher therapy costs and potential supply delays. Positively, tariffs have encouraged local production of biosimilars, investments in domestic manufacturing infrastructure, and innovation in cost-effective antibody development.

The anti-cd20 monoclonal antibodies market research report is one of a series of new reports that provides anti-cd20 monoclonal antibodies market statistics, including anti-cd20 monoclonal antibodies industry global market size, regional shares, competitors with a anti-cd20 monoclonal antibodies market share, detailed anti-cd20 monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cd20 monoclonal antibodies industry. This anti-cd20 monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-CD20 monoclonal antibodies are targeted immunotherapies designed to bind to the CD20 protein found on the surface of B cells. These antibodies initiate immune mechanisms such as complement activation and antibody-dependent cell-mediated cytotoxicity to destroy abnormal or malignant B cells. This targeted strategy allows for more precise treatment while reducing systemic side effects compared with conventional chemotherapy.

The main types of anti-CD20 monoclonal antibodies include rituximab, obinutuzumab, ofatumumab, and others. Rituximab is a monoclonal antibody that targets CD20 and is used in the treatment of B-cell malignancies and autoimmune disorders by eliminating abnormal B cells. It is administered through various routes, including intravenous and subcutaneous, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used across a range of applications, including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, and other conditions, and is utilized by end users such as hospitals, surgical and diagnostic centers, maternity centers, ambulatory care centers, research and academic institutions, and others.

The anti-CD20 monoclonal antibodies market consists of sales of tositumomab, ocrelizumab, ublituximab, and mosunetuzumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.